Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, pilot-study to evaluate the effect of Interleukin-1
blockade on exercise capacity in patients with heart failure. Subjects will undergo
cardiopulmonary exercise testing at baseline and after 2-weeks treatment with anakinra
(recombinant human Interleukin-1 receptor antagonist).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborators:
National Center for Research Resources (NCRR) National Institutes of Health (NIH)